Brokerages Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Price Target at $9.31

Trevi Therapeutics, Inc. (NASDAQ:TRVI) has earned an average recommendation of “Buy” from the ten research firms that are covering the firm, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $9.31.

TRVI has been the topic of a number of analyst reports. D. Boral Capital reaffirmed a “buy” rating and issued a $21.00 price target on shares of Trevi Therapeutics in a research note on Monday. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price target on shares of Trevi Therapeutics in a research note on Thursday, December 12th. Finally, HC Wainwright lifted their price target on Trevi Therapeutics from $6.00 to $7.50 and gave the stock a “buy” rating in a research note on Thursday, December 12th.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Point72 Asset Management L.P. purchased a new stake in Trevi Therapeutics during the fourth quarter valued at approximately $17,099,000. Frazier Life Sciences Management L.P. increased its holdings in Trevi Therapeutics by 44.5% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company’s stock valued at $43,939,000 after buying an additional 3,283,684 shares during the last quarter. Woodline Partners LP increased its holdings in Trevi Therapeutics by 429.9% during the fourth quarter. Woodline Partners LP now owns 3,212,597 shares of the company’s stock valued at $13,236,000 after buying an additional 2,606,370 shares during the last quarter. Adage Capital Partners GP L.L.C. purchased a new stake in Trevi Therapeutics during the fourth quarter valued at approximately $10,300,000. Finally, Acorn Capital Advisors LLC purchased a new stake in Trevi Therapeutics during the fourth quarter valued at approximately $8,244,000. 95.76% of the stock is owned by hedge funds and other institutional investors.

Trevi Therapeutics Price Performance

NASDAQ:TRVI opened at $4.50 on Friday. The business has a 50 day moving average of $4.11 and a 200 day moving average of $3.44. The company has a market capitalization of $345.90 million, a price-to-earnings ratio of -10.23 and a beta of 0.88. Trevi Therapeutics has a 1-year low of $2.30 and a 1-year high of $5.05.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.